Ftse Mib
35.355,87
0,58%
DAX
18.869,36
0,78%
S&P 500
5.300,42
1,02%
NASDAQ
16.733,91
1,35%
Bitcoin
65.435,16
6,32%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Moleculin Biotech Inc (MBRX) Moleculin Biotech Inc (MBRX) Notizie

MBRX

Moleculin Biotech (MBRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MBRX
DataOraFonteTitoloSimboloCompagnia
15/05/202414:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
15/05/202414:38PR Newswire (US)Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)NASDAQ:MBRXMoleculin Biotech Inc
13/05/202416:53Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
13/05/202413:30PR Newswire (US)Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MBRXMoleculin Biotech Inc
10/05/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBRXMoleculin Biotech Inc
09/05/202414:30PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
08/05/202414:45PR Newswire (US)Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
07/05/202414:55PR Newswire (US)Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataNASDAQ:MBRXMoleculin Biotech Inc
02/05/202415:00PR Newswire (US)Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024NASDAQ:MBRXMoleculin Biotech Inc
01/05/202414:50PR Newswire (US)Moleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
18/04/202414:30PR Newswire (US)European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
10/04/202414:30PR Newswire (US)Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesNASDAQ:MBRXMoleculin Biotech Inc
28/03/202415:45PR Newswire (US)Moleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceNASDAQ:MBRXMoleculin Biotech Inc
27/03/202414:25PR Newswire (US)Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityNASDAQ:MBRXMoleculin Biotech Inc
27/03/202414:05PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLNASDAQ:MBRXMoleculin Biotech Inc
25/03/202412:30PR Newswire (US)Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialNASDAQ:MBRXMoleculin Biotech Inc
22/03/202421:05PR Newswire (US)Moleculin Reports Full Year 2023 Financial ResultsNASDAQ:MBRXMoleculin Biotech Inc
20/03/202412:30PR Newswire (US)Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
20/03/202412:15IH Market NewsJPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest NewsNASDAQ:MBRXMoleculin Biotech Inc
19/03/202421:30PR Newswire (US)Moleculin Announces Reverse Stock SplitNASDAQ:MBRXMoleculin Biotech Inc
12/03/202414:05PR Newswire (US)Moleculin to Present at the 36th Annual ROTH ConferenceNASDAQ:MBRXMoleculin Biotech Inc
16/02/202423:19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBRXMoleculin Biotech Inc
13/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBRXMoleculin Biotech Inc
02/02/202423:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBRXMoleculin Biotech Inc
24/01/202414:50PR Newswire (US)Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3NASDAQ:MBRXMoleculin Biotech Inc
16/01/202423:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
05/01/202423:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
27/12/202313:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBRXMoleculin Biotech Inc
22/12/202323:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBRXMoleculin Biotech Inc
21/12/202303:16PR Newswire (US)Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketNASDAQ:MBRXMoleculin Biotech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MBRX

La tua Cronologia

ASX
MMMDA
Marley Spoon
AMEX
BLN
COIN
SCOIETH
SprinkleCoin
BMF
VF2F25C001100
VF2F25C001100 - 01/2025
HITB
BISTUSD
Bistroo Token
BIT
P12A18
BNP PARIBAS ISSUANCE
BIT
P117Z4
Bnp Paribas Issuance
NASDAQ
FSRUOX
Global Bond Income Close...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network